Viatris reported $14.7B of revenue over the trailing twelve months, +4.4% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $14.7B (to Q2 2026). Net income: −$411M, trailing twelve months to Q2 2026. Free cash flow: $1.95B, trailing twelve months to Q2 2026. Operating margin: −0.64%, trailing twelve months to Q2 2026.

VTRSViatris

Healthcare

$18.00+83% 1Y

$18.00

$9.8452 weeks$18.66

VTRS as reported

Viatris reported $14.7B of revenue over the trailing twelve months, +4.4% on the year before. 11 reported series are charted on this page, each one as filed.

$14.7B

Revenue, trailing twelve months · to Q2 2026 · +4.4% against the twelve months before

Net income: −$411M
Net income · −88% year on year · trailing twelve months to Q2 2026
Free cash flow: $1.95B
Free cash flow · +12% year on year · trailing twelve months to Q2 2026
Operating margin: −0.64%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for VTRS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$14.7B	+4.4%	Q2 2026
Net income	−$411M	−88%	Q2 2026
EPS	−$0.36	−88%	Q2 2026
Gross margin	35%	n/a	Q2 2026
Operating margin	−0.64%	n/a	Q2 2026
Net margin	−2.7%	n/a	Q2 2026
ROE	−13%	n/a	Q2 2026
ROA	−5.3%	n/a	Q2 2026
ROIC	−3.7%	n/a	Q2 2026
Free cash flow	$1.95B	+12%	Q2 2026
P/E	52.9	n/a	Q4 2023 · 10 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.